Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
San-Juan-Rodriguez A, Gellad WF, Good CB, Hernandez I. Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition. JAMA Netw Open. 2019;2(12):e1917379. doi:10.1001/jamanetworkopen.2019.17379
Biosimilars hold promise for reducing spending on biologics.1 Biosimilar prices are estimated to be 15% to 16% lower than originator products,2 but it is unclear how list prices, net prices, and discounts for the originator products change with biosimilar competition.
We selected filgrastim, pegfilgrastim, infliximab, and insulin glargine as case studies because these were the only originator biologics that, by December 2018, faced competition from biosimilars (filgrastim-sndz, filgrastim-aafi, pegfilgrastim-jmdb, infliximab-dyyb, and infliximab-abda) or from other within-molecule substitutes (tbo-filgrastim and insulin glargine [Basaglar; Lilly]).3
We obtained pricing data from January 2007 to June 2018 from SSR Health,4 which provides quarterly estimates of list prices, net prices, Medicaid discounts, and discounts in other payers for branded products with US sales reported by publicly traded companies. Quarterly net prices are calculated as the ratio between sales and number of units sold. Discounts are calculated as the ratio between the difference in list and net prices (numerator) and the list prices (denominator). Net prices and discounts capture all manufacturer concessions and not solely rebates.4 For each drug and year, we calculated the mean list and net prices and the mean discounts in Medicaid and other payers.5
Create a personal account or sign in to: